72° sunny Silicon Beach

Celenex

Acquired by: Amicus Therapeutics

Celenex delivers a life-saving gene therapy treatment that cures children with Batten disease, a group of severe neurodegenerative disorders characterized by loss of vision, breakdown of motor skills and ongoing seizures. Unlike other therapies that use painful and frequent treatments that are only able to reduce symptoms, Celenex takes a curative approach for juvenile patients suffering from these rare and ultra-rare genetic diseases in order to cure the cause. Backed by a diverse team including the leading innovator in gene therapy, successful technology entrepreneurs and the father of two young daughters battling Batten Disease, Celenex is powered by industry visionaries who are steadfast on bringing this ground-breaking treatment to market, in order to save lives.

For more Info: https://www.genengnews.com/news/amicus-expands-into-gene-therapy-with-celenex-acquisition/

https://xconomy.com/new-york/2018/09/20/amicus-shells-out-100m-for-celenex-and-dives-into-gene-therapy/